share_log

B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5

B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5

Bof A Securities將Achilles Therapeutics的評級下調至表現不佳,將目標股價下調至0.5美元
Benzinga ·  2023/12/14 07:18

B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers the price target from $7 to $0.5.

B of A Securities分析師塔澤恩·艾哈邁德將Achilles Therapeutics(納斯達克股票代碼:ACHL)的評級從買入下調至表現不佳,並將目標股價從7美元下調至0.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論